[NASDAQ:RGEN] REPLIGEN CORPORATION > 5.34
Repligen Corporation, a biopharmaceutical company, engages in the research and development of therapeutics for the treatment of central nervous system diseases. It manufactures and markets Protein A product, which is used in the production of various therapeutic monoclonal antibodies. The company also markets SecreFlo, a synthetic form of the hormone secretin, which is used as an aid in the diagnosis of certain diseases of the pancreas. Repligen sells Protein A products to chromatography companies, diagnostics companies, biopharmaceutical companies, and laboratory researchers primarily through value-added resellers and distributors in the United States and internationally; and markets SecreFlo directly to gastroenterologists in the United States. The company also conducts drug development programs for diseases, such as bipolar disorder and neurodegeneration. Its development stage products include RG1068, a Phase II clinical trial product that improve the detection of structural abnormalities of the pancreatic ducts during MRI imaging of the pancreas; and RG2417, a Phase II clinical trial product, is a biological compound used for the synthesis of DNA and RNA in patients with bipolar depression.
Wednesday April 16, 4:43 pm ET
FDA grants 'fast track' designation to Repligen drug for use in pancreatic imaging procedure
biz.yahoo.com
 |
